Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson’s disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. “We’re proud of the momentum we’ve built across our development programs. With SER-252 on trackRead More